Iatrogenic skin injury in hospitalized patients

Clinics in Dermatology

Volumn 29, Issue 6, 2011, Pages 622-632

  Cheng, Carol E ^a   Kroshinsky, Daniela ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; ANTICONVULSIVE AGENT; ATORVASTATIN; CAPTOPRIL; CEPHALOSPORIN; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; DICLOFENAC; DICLOXACILLIN; FUROSEMIDE; GOLD SALT; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; LITHIUM; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN G; PHENYTOIN; PREDNISONE; SULFAPYRIDINE; SULFONAMIDE; UNINDEXED DRUG; VANCOMYCIN;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANETODERMA; BANDAGES AND DRESSINGS; BURN UNIT; CATHETER THROMBOSIS; CLINICAL FEATURE; CONTACT DERMATITIS; COXSACKIE VIRUS B4; CYTOMEGALOVIRUS INFECTION; DECUBITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRESS SYNDROME; DRUG MEGADOSE; DRUG WITHDRAWAL; HOSPITAL PATIENT; HUMAN; HUMAN PARVOVIRUS B19; IATROGENIC DISEASE; IMMUNOADSORPTION; IMPLANT; LINEAR IGA BULLOUS DERMATOSIS; NOTE; OPHTHALMOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SECONDARY INFECTION; SKIN ALLERGY; SKIN CALCIFICATION; SKIN DISEASE; SKIN INJURY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIRUS INFECTION;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANETODERMA; CALCINOSIS; DERMATITIS, CONTACT; DRUG HYPERSENSITIVITY; EPIDERMAL NECROLYSIS, TOXIC; HOSPITALIZATION; HUMANS; IATROGENIC DISEASE; LIP DISEASES; PRESSURE ULCER; PYODERMA GANGRENOSUM; SKIN; SKIN DISEASES; SKIN DISEASES, VESICULOBULLOUS;

EID: 80054755700     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.08.006     Document Type: Note

References (76)

1. Leape L.L., Brennan T.A., Laird N., et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med 1991, 324:377-384.
2. Brennan T.A., Leape L.L., Laird N.M., et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med 1991, 324:370-376.
3. Thomas E.J., Studdert D.M., Runciman W.B., et al. A comparison of iatrogenic injury studies in Australia and the USA. I: context, methods, casemix, population, patient and hospital characteristics. Int J Qual Health Care 2000, 5:371-378.
4. Walsh S.A., Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol 2011, 36:6-11.
5. Um S.J., Lee S.K., Kim Y.H., et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol 2010, 20:556-562.
6. England Owen C., Stratman E.J. Failure to recognize and manage patients with DRESS. Arch Dermatol 2010, 146:1379.
7. Chen Y.C., Chiu H.C., Chu C.Y. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010, 146:1373-1379.
8. Jeung Y.J., Lee J.Y., Oh M.J., et al. Comparison of the causes and clinical features of drug rash with eosinophilia and systemic symptoms and Stevens-Johnson syndrome. Allergy Asthma Immunol Res 2010, 2:123-126.
9. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2007, 156:609-610.
10. Tohyama M., Hashimoto K. New aspects of drug-induced hypersensitivity syndrome. J Dermatol 2011, 38:222-228.
11. Navi D., Michael D.J., Fazel N. Drug-induced linear IgA bullous dermatosis. Dermatol Online J 2006, 12:12.
12. McDonald H.C., York N.R., Pandya A.G. Drug-induced linear IgA bullous dermatosis demonstrating the isomorphic phenomenon. J Am Acad Dermatol 2010, 62:897-898.
13. Schwendiman MN, Turiansky GW. What is your diagnosis? Linear IgA dermatosis. Cutis 2010;86:117, 125-8.
14. Torres T., Sanches M., Selores M. Linear IgA bullous disease in a patient with Crohn's disease. Acta Dermatovenerol Alp Panonica Adriat 2010, 19:29-31.
15. Joshi S., Scott G., Looney R.J. A successful challenge in a patient with vancomycin-induced linear IgA dermatosis. Ann Allergy Asthma Immunol 2004, 93:101-103.
16. Wiadrowski T.P., Reid C.M. Drug-induced linear IgA bullous disease following antibiotics. Australas J Dermatol 2001, 42:196-199.
17. Kasperkiewicz M., Meier M., Zillikens D., et al. Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 2010, 220:259-263.
18. Bolognia J., Jorizzo J., Rapini R. Dermatology 2003, 291-299. Elsevier, London.
19. Bastuji-Garin S., Fouchard N., Betocchi M., et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000, 115:149-153.
20. Yun S.J., Choi M.S., Piao M.S., et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology 2008, 217:254-259.
21. Momin S.B. Review of intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. J Clin Aesthet Dermatol 2009, 2:51-58.
22. Palmieri T., Greenhalgh D.G., Saffle J.R., et al. A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century. J Burn Care Rehabil 2002, 23:87-96.
23. Schulz J., Sheridan R.L., Ryan C.M., et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000, 21:199-204.
24. Shammas M., Edward C., Sarkar J., et al. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthamology 2010, 149:203-213.
25. Worswick S., Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther 2011, 24:207-218.
26. Teo L., Tay Y.K., Liu T.T., et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options. Singapore Med J 2009, 50:29-33.
27. Prins C., Kerdel F., Padilla R., et al. Treatment of toxic epidermal necrolysis with highdose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003, 139:26-32.
28. Schneck J., Fagot J., Sekula P., et al. Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008, 58:33-40.
29. Arevalo J., Lorenta J., Gonzalez-Herrada C., et al. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000, 48:473-478.
30. Fischer M., Fiedler E., Marsch W., et al. Antitumor necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002, 146:707-708.
31. Hunger R., Hunziker T., Buettiker U., et al. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J All Clin Immunol 2005, 116:923-924.
32. Al-Shouli S., Abouchala N., Bogusz M., et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 2005, 85:534-535.
33. Meiss F., Heimbold P., Meykadeh N., et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007, 21:717-719.
34. Wojtkiewicz A., Wysocki M., Fortuna J., Chrupek M., Matczuk M., Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol 2008, 88:420-421.
35. Sidoroff A., Dunant A., Viboud C., et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007, 157:989-996.
36. Davidovici B., Dodiuk-Gad R., Rozenman D., et al. Profile of acute generalized exanthematous pustulosis in Israel during 2002-2005:results of the RegiSCAR Study. Isr Med Assoc J 2008, 10:410-412.
37. Lee H.Y., Chou D., Pang S.M., et al. Acute generalized exanthematous pustulosis: analysis of cases managed in a tertiary hospital in Singapore. Int J Dermatol 2010, 49:507-512.
38. Mailhol C., Lauwers-Cances V., Rancé F., et al. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy 2009, 64:801-806.
39. Liippo J., Kousa P., Lammintausta K. The relevance of chlorhexidine contact allergy. Contact Dermatitis 2011, 64:229-234.
40. Velázquez D., Zamberk P., Suárez R., et al. Allergic contact dermatitis to povidone-iodine. Contact Dermatitis 2009, 60:348-349.
41. Lee S., Zhai H., Maibach H. Allergic contact dermatitis from iodine preparations: a conundrum. Contact Dermatitis 2005, 52:184-187.
42. Kozuka T. Patch testing to exclude allergic contact dermatitis caused by povidone-iodine. Dermatol ogy 2002, 204:96-98.
43. Iijima S., Kuramochi M. Investigation of irritant skin reaction by 10% povidone-iodine solution after surgery. Dermatology 2002, 204(suppl 1):103-108.
44. Widman T.J., Oostman H., Storrs F.J. Allergic contact dermatitis from medical adhesive bandages in patients who report having a reaction to medical bandages. Dermatitis 2008, 19:32-37.
45. Rühlemann D., Kügler K., Mydlach B., et al. Contact dermatitis to self-adhesive ECG electrodes. Contact Dermatitis 2010, 62:314-315.
46. El-Dars L.D., Chaudhury W., Hughes T.M., et al. Allergic contact dermatitis to Dermabond after orthopaedic joint replacement. Contact Dermatitis 2010, 62:315-317.
47. Zug K.A., Warshaw E.M., Fowler J.F., et al. Patch-test results of the North American Contact Dermatitis Group 2005-2006. Dermatitis 2009, 20:149-160.
48. Yoo J.Y., Al Naami M., Markowitz O., et al. Allergic contact dermatitis: patch testing results at Mount Sinai Medical Center. Skinmed 2010, 8:257-260.
49. Paauw J.D., Borders H., Ingalls N., et al. The incidence of PICC line-associated thrombosis with and without the use of prophylactic anticoagulants. JPEN J Parenter Enteral Nutr 2008, 32:443-447.
50. Koo K., Brem H., Lebwohl M. Pyoderma gangrenosum versus chronic venous ulceration: comparison of diagnostic features. J Cutan Med Surg 2006, 10:26-30.
51. Callen J.P., Jackson M.J. Pyoderma gangrenosum: an update. Rheum Dis Clin N Am 2007, 33:787-802.
52. Miller J., Yentzer B.A., Clark A., et al. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010, 62:646-654.
53. Fonder M.A., Lazarus G.S., Cowan D.A., et al. Treating the chronic wound: a practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol 2008, 58:185-206.
54. Bellini V., Simonetti S., Lisi P. Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol 2008, 22:113-115.
55. Brooklyn T.N., Dunnill M.G., Shetty A., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505-509.
56. Kerns M.J., Graves J.E., Smith D.I., et al. Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg 2006, 25:226-240.
57. Honari G., Ellis S.G., Wilkoff B.L., et al. Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis 2008, 59:7-22.
58. Hallab N., Merritt K., Jacobs J.J. Metal sensitivity in patients with orthopaedic implants. J Bone Joint Surg Am 2001, 83:428-436.
59. Alonge L., Kroen M. Information for physicians on sub-acute thromboses (SAT) and hypersensitivity reactions with use of the Cordis CYPHER™ coronary stent 2003, FDA, Rockville, MD, Accessed June 15, 2011. http://www.fda.gov/cdrh/safety/cypher.html.
60. Colditz P.B., Dunster K.R., Joy G.J., Robertson I.M. Anetoderma of prematurity in association with electrocardiographic electrodes. J Am Acad Dermatol 1999, 41:479-481.
61. Goujon E., Beer F., Gay S., et al. Anetoderma of prematurity: an iatrogenic consequence of neonatal intensive care. Arch Dermatol 2010, 146:565-567.
62. Moss J., Syrengelas A., Antaya R., et al. Calcinosis cutis: a complication of intravenous administration of calcium gluconate. J Cutan Pathol 2006, 33(suppl 2):60-62.
63. Vanderwee K., Defloor T., Beeckman D., et al. Assessing the adequacy of pressure ulcer prevention in hospitals: a nationwide prevalence survey. BMJ Qual Saf 2011, 20:260-267.
64. Bergstrom N., Braden B.J., Laguzza A., Holman V. The Braden Scale for predicting pressure sore risk. Nurs Res 1987, 36:205-210.
65. Bergstrom N., Braden B.J., Kemp M., et al. Reliability and validity of the Braden Scale: a multi-site study. Nurs Res 1998, 47:261-269.
66. Bergstrom N., Braden B., Kemp M., et al. Multi-site study of incidence of pressure ulcers and the relationship between risk level, demographic characteristics, diagnoses, and prescription of preventive interventions. J Am Geriatr Soc 1996, 44:22-30.
67. Jenkins M.L., O'Neal E. Pressure ulcer prevalence and incidence in acute care. Adv Skin Wound Care 2010, 23:556-559.
68. European Pressure Ulcer Advisory Panel and National Pressure Ulcer Advisory Panel Prevention and treatment of pressure ulcers: quick reference guide 2009, National Pressure Ulcer Advisory Panel, Washington DC.
69. Allen V., Ryan D.W., Murray A. Potential for bed sores due to high pressures: influence of body sites, body position, and mattress design. Br J Clin Pract 1993, 47:195-197.
70. Allen V., Ryan D.W., Murray A. Air-fluidized beds and their ability to distribute interface pressures generated between the subject and the bed surface. Physiol Meas 1993, 14:359-364.
71. Reddy M., Gill S.S., Rochon P.A. Preventing pressure ulcers: a systematic review. JAMA 2006, 296:974-984.
72. Defloor T., De Bacquer D., Grypdonck M.H. The effect of various combinations of turning and pressure reducing devices on the incidence of pressure ulcers. Int J Nurs Stud 2005, 42:37-46.
73. Moore Z.E., Cowman S. Repositioning for treating pressure ulcers. Cochrane Database Syst Rev 2009, CD006898.
74. Lohi J., Sipponen A., Jokinen J.J. Local dressings for pressure ulcers: what is the best tool to apply in primary and second care?. J Wound Care 2010, 19:123-127.
75. Reddy M., Gill S.S., Kalkar S.R., et al. Treatment of pressure ulcers: a systematic review. JAMA 2008, 300:2647-2662.
76. Armstrong M.H., Price P. Wet-to-dry gauze dressings: fact and fiction. Wounds 2004, 16:56-62.